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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological 123 
agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection 124 
caused by introduction of a novel coronavirus into humans in late 2019 in China’s 125 
Hubei province. As of July 24, 2020, SARS-CoV-2 has spread to 215 countries, has 126 
infected more than 16 million people, and has caused more than 640,000 deaths. Since 127 
humans do not have pre-existing immunity against SARS-CoV-2, there is an urgent 128 
need to develop therapeutics and vaccines to mitigate the current pandemic and to 129 
prevent the re-emergence of COVID-19 in the future. In February 2020 the World Health 130 
Organization (WHO) assembled an international panel of experts to develop animal 131 
models for COVID-19 to accelerate testing of vaccines and therapeutics. This review 132 
summarizes the findings to date and provides relevant information for preclinical 133 
testing of COVID-19 vaccine candidates and therapeutics.  134 
 135 
Although there are discrepancies in the estimated case-fatality ratio (CFR) of COVID-19 in 136 
humans, it is clear that severity is age-stratified and that the CFR in patients over 65 years of 137 
age is likely higher than 1% 1. Initially, infection with SARS-CoV-2 is characterized by a range 138 
of mild symptoms, including fever, cough, dyspnea and myalgia 2.  Partly these are caused by 139 
the capacity of SARS-CoV-2 to replicate efficiently in the upper respiratory tract. While most 140 
patients subsequently resolve the infection, the disease may also progress to severe 141 
pneumonia.  In severe cases, bilateral lung involvement with ground-glass opacities are the 142 
most common chest computed tomography (CT) findings. Disease progression can then 143 
involve acute respiratory distress syndrome (ARDS), and in some cases an inflammatory 144 
syndrome resembling septic shock.  Histological examination of the lungs of patients showed 145 
bilateral diffuse alveolar damage (DAD), pulmonary edema and hyaline membrane formation 146 
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3. COVID-19 is also characterized by damage to other organ systems associated with 147 
coagulopathy and characterized by elevated fibrinogen and D-dimer levels, indicating 148 
increased thrombus generation and fibrinolysis 4. Those at higher risk of severe COVID-19 149 
are individuals with underlying conditions such as obesity, diabetes, hypertension, chronic 150 
respiratory disease and cardiovascular disease 1.  151 
 152 
Through the ‘Solidarity’ trials, the WHO has launched a global campaign to test therapeutics 153 
and vaccines on an unprecedented scale 5.  In order to test these and other potential medical 154 
countermeasures, it is imperative to identify animal models for COVID-19 that provide 155 
measurable readouts for potential interventions and that utilize representative virus isolates 6. 156 
To this end, the WHO R&D Blueprint team established an ad hoc expert working group 157 
focused on COVID-19 disease modelling (WHO-COM).  In this review we provide a summary 158 
of the current literature on COVID-19 animal models (Supplementary Table 1), including 159 
studies generated by the WHO-COM group since February 2020, which we hope will serve to 160 
facilitate further preclinical analysis of vaccines and therapeutics.  161 
 162 
Mouse Models 163 
 164 
The main impediment for SARS-CoV-2 infection of murine cells is the lack of appropriate 165 
receptors to initiate viral infection.  SARS-CoV-2, like SARS-CoV, uses the cellular surface 166 
protein angiotensin-converting enzyme 2 (ACE2) to bind and enter cells, and murine ACE2 167 
does not effectively bind the viral spike protein 7. To solve this problem some strategies have 168 




Virus adaptation to mACE2 171 
The spike protein of SARS-CoV-2 can be modified to gain effective binding to murine ACE2. 172 
One strategy is sequential passaging of SARS-CoV-2 in mouse lung tissue 8. This method is 173 
successful because RNA virus populations consist of a mutant swarm of closely related viral 174 
quasispecies. Rare viruses in the swarm containing spike mutations that increase their 175 
binding affinity to murine ACE2 are expected to be selected due to their higher levels of 176 
replication in murine lungs. Alternatively, mouse adaptation of SARS-CoV-2 can be achieved 177 
using reverse genetics to modify the receptor-binding domain (RBD) of the virus so that it can 178 
infect murine cells via the mouse ACE2 protein. Using these approaches, mice were 179 
sensitized for infection but developed very mild disease 9. It is likely that additional efforts 180 
aimed at mouse-adaptation will result in the outgrowth of additional virus variants that can 181 
cause more severe disease. These mice will be useful for pathogenesis studies and for 182 
studies of antivirals and vaccines. One potential caveat is that the mutations in the SARS-183 
CoV-2 spike protein that enhance affinity for the mouse ACE2 receptors are located in the 184 
receptor binding domain, the primary target for the neutralizing antibody response. These 185 
mutations could result in a wild type virus neutralizing mAb being falsely considered non-186 
neutralizing. 187 
 188 
Expression of human ACE2 in genetically modified mice 189 
A different approach consists of modifying the mice to express hACE2. There are currently 190 
three transgenic models in which hACE2 is under the expression of a tissue-specific promoter 191 
(e.g., for epithelial cells, Krt18 10), a universal promoter (CMV enhancer followed by the 192 
chicken beta-actin promoter 11), or the endogenous mACE2 promoter 12. All of these mice are 193 
susceptible to infection by SARS-CoV-2, but the differences in hACE2 expression result in a 194 
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pathogenic range from mild to lethal disease. In particular, with the exception of the model in 195 
which hACE2 is controlled by the mouse ACE2 promoter, all other models develop 196 
encephalitis after infection with SARS-CoV 13 or SARS-CoV-2 14. However, while SARS-CoV 197 
infection of K18-hACE2 mice results in a highly lethal encephalitis, the neurological infection 198 
caused by SARS-CoV-2 infection in these mice is less severe. Some mice appear to 199 
succumb to severe pneumonia, at times when the brain infection is not substantial 15. These 200 
mouse models provide a stringent test for vaccine and therapeutic efficacy and may be useful 201 
for studies of pathogenesis.  202 
 203 
An alternative approach that mirrors tissue-specific expression of human ACE2 is to 204 
substitute the mACE2 gene by the hACE2 gene.  Similar models expressing human dipeptidyl 205 
peptidase-4 (DPP4), the Middle East respiratory syndrome coronavirus (MERS-CoV) 206 
receptor, have been successfully developed 16-18. One such hACE2 humanized mouse has 207 
now been reported, and supports replication of SARS-CoV-2 in respiratory and brain tissues, 208 
although mice do not develop severe disease 19.  However, more severe disease is expected 209 
to occur in hACE2 knock-in mice if virus is passaged serially through mouse lungs. Overall, 210 
these mice will probably be very useful models of human disease especially if combined with 211 
viral adaptation that increases virulence of SARS-CoV-2 in mice. 212 
 213 
Finally, instead of permanent genetic modification, it is also possible to generate mice 214 
susceptible to SARS-CoV-2 infection by sensitizing the respiratory tract of these animals to 215 
SARS-CoV-2 replication through transduction with adenovirus (Ad5) or adeno-associated 216 
virus (AAV) expressing hACE2.  This system, pioneered for MERS studies 20, allows transient 217 
replication of SARS-CoV-2 in lungs of mice for several days until immune clearance, and it 218 
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has the advantage that it can be applied quickly to different strains of mice. Upon infection 219 
with SARS-CoV-2, Ad5-hACE2 mice develop a widespread infection of the lungs and 220 
histopathological changes consistent with a viral pneumonia. Mice developed clinical disease 221 
characterized by changes in body scoring (hunching) and weight loss. Virus is generally 222 
cleared by 7 days after infection, although not in some immunocompromised mice 21 14. Mice 223 
sensitized via AAV-hACE2 delivery are also susceptible to SARS-CoV-2 infection, but virus 224 
replication seems to be lower than in Ad5-hACE2 transduced mice 22. Ad5-hACE2 and AAV-225 
hACE2 sensitized mice are useful for evaluating vaccines and antiviral therapies, as well 226 
identifying SARS-CoV-2-specific antibody and T cell epitopes. A limitation with these mice, as 227 
well as in some of the transgenic hACE2 mice, is that hACE2 is expressed ectopically, which 228 
may change the tissue or cellular tropism of the virus. 229 
 230 
Other mouse models and approaches 231 
Additional ongoing efforts to develop mouse models for SARS-CoV-2 infection studies involve 232 
mice humanized with hACE2 and human hematopoiesis, and Collaborative-Cross (CC) 233 
mouse studies. Mice transplanted with human immune cells or human immune system (HIS) 234 
mice,  have been widely used to study human-specific viral infections 23,24 and the 235 
combination of HIS and ACE2 expression could help to further explore the efficacy of 236 
vaccines and therapies, in particular those that modulate human immune cells. Similarly, 237 
previous studies using the CC model of genetic diversity, a panel of recombinant inbred mice 238 
with expanded susceptibility to viruses that normally do not cause disease in laboratory mice 239 
can be used to enhance virus disease susceptibility, however, infection remains heavily 240 
dependent on a functional entry receptor 25,26. CC mice were previously used with mouse-241 
adapted SARS-CoV to identify mechanisms of pathogenesis and genetic loci that determine 242 
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susceptibility 27. Presumably, CC studies could enable exploration of an expanded range of 243 
SARS-CoV-2 phenotypes in mice that potentially better recapitulate human disease, as 244 
mouse adapted strains become available.  245 
 246 
In summary, a variety of murine models for mild and severe COVID-19 have been described, 247 
or are under development. All will be useful for vaccine and antiviral evaluation and some 248 
share features with the human disease. No murine model at present recapitulates all aspects 249 
of human COVID-19, especially unusual features such as the pulmonary vascular disease 250 
and hyperinflammatory syndromes observed in adults and children, respectively 28,29. 251 
However, continued refinement may eventually result in models for even these aspects of the 252 
human disease. 253 
 254 
Syrian Hamster Model 255 
 256 
Syrian hamsters (Mesocricetus auratus) are small mammals that have been used as animal 257 
models for other respiratory viruses, including SARS-CoV, influenza virus, and adenovirus 30-258 
33. In silico comparison of the angiotensin-converting enzyme 2 (ACE2) sequence of humans 259 
known to interact with the SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD) 260 
with that of hamsters 34 suggested that Syrian hamsters might be susceptible to SARS-CoV-2 261 
infection. Indeed, upon experimental intranasal infection, Syrian hamsters show mild to 262 
moderate disease with progressive body weight loss starting very early after infection (days 1-263 
2 post-inoculation). All animals challenged by different groups and with different SARS-CoV-2 264 
isolates consistently showed respiratory signs, including labored breathing 34,35. Additional 265 
signs of morbidity included lethargy, ruffled fur and hunched posture 34. After two weeks of 266 
10 
 
infection, hamsters typically recovered. Of particular interest is the fact that SARS-CoV-2 267 
infection in hamsters reflect some of the demographic differences of COVID-19 in humans. 268 
Thus, aged hamsters as well as male hamsters seem to develop a more severe disease than 269 
young and female hamsters respectively 36,37 (Table 1).  270 
 271 
SARS-CoV-2 disease in hamsters is associated with high levels of virus replication and 272 
histopathological evidence of disease, which included ground glass opacities and evidence of 273 
gas in the cavity surrounding the lungs 37. These findings are similar to those previously 274 
reported for SARS-CoV infection in this model 31. Viral RNA is readily detected in the 275 
respiratory tract and other tissues, such as the small intestine, which could be useful for the 276 
evaluation of therapeutics and vaccines. Virus transmission to cage mates has also been 277 
observed 34, suggesting that hamsters could be useful in transmission studies. Histologically, 278 
inflammatory infiltrates with abundant viral antigen expression and apoptosis were observed 279 
in the upper and lower respiratory tract starting at 2 days post-infection (dpi), being most 280 
severe at 4 dpi and resolving at 14 dpi. Among the non-respiratory tract tissues, only the 281 
intestine demonstrated viral antigen expression in association with severe epithelial cell 282 
necrosis, damaged and deformed intestinal villi, and increased lamina propria mononuclear 283 
cell infiltration. Lung disease was also demonstrated by CT. High-resolution micro-CT scans 284 
showed airway dilation and significant consolidations in the lungs of infected hamsters 35. A 285 
quantitative analysis revealed an increase of the non-aerated lung volume in these hamsters. 286 
This method thus allows quantitative monitoring of disease without the need of euthanizing 287 




Expression of chemokines/cytokines in the lungs of hamsters peaked at 4 dpi and then 290 
gradually resolved at 7 dpi. Interferon-γ and proinflammatory chemokines/cytokines were 291 
potently induced at 2 dpi and 4 dpi and dropped to the baseline level at 7 dpi. SARS-CoV-2 292 
induced lung pathology in hamsters appears to be driven by immune pathology, as lung injury 293 
at 4 dpi is markedly reduced in STAT2 knockout hamsters while viral loads are massively 294 
increased and viral RNA disseminated in multiple peripheral tissues 35. Serum neutralizing 295 
antibodies were detected as early as 7 dpi. Passive immunization of naïve hamsters with 296 
these convalescent serum samples resulted in significantly reduced respiratory tract viral 297 
loads but no obvious improvement in clinical signs and histological changes. Furthermore, 298 
SARS-CoV-2 can be transmitted between hamsters via close contact and non-contact routes 299 
34,38. Transmission via fomites on the other hand was possible, but not efficient 38.  300 
 301 
Since studies in hamsters can be completed quickly and in a cost-effective manner, there is 302 
an increasing interest in the use of this model for screening of therapeutics. Until now, lack 303 
of/or limited efficacy was demonstrated for the re-purposed drugs hydroxychloroquine (with or 304 
without azithromycin) and favipiravir 39,40, whereas a YF17D-vectored SARS-CoV-2 vaccine 305 
candidate conferred efficient protection against SARS-CoV-2 challenge in hamsters 41. 306 
Adoptive transfer of SARS-CoV-2 neutralizing antibodies protected hamsters from SARS-307 
CoV-2-induced disease 42. A putative caveat of the model is the lack of research tools for this 308 
species which are still scarce compared for example with those for mice.  309 
 310 




Ferrets (Mustela putorius furo) have been shown to be a highly valuable model to test 313 
pathogenicity and transmission of human respiratory viruses, including influenza virus and 314 
respiratory syncytial virus (RSV) 43,44. It is thus not surprising that the ferret model has been 315 
investigated for studies of COVID-19 pathogenesis and SARS-CoV-2 transmission. Despite 316 
the use of different isolates of SARS-CoV-2, the results have been remarkably consistent 317 
across all laboratories. 318 
 319 
Following mucosal exposure with SARS-CoV-2, clinical alterations in ferrets are undetectable 320 
or mild and may include lethargy, nasal discharge, wheezing, oropharyngeal mucus buildup, 321 
sneezing, and loose stool 45.  Ferrets infected by small-particle aerosol had similar disease, 322 
albeit at 100-fold lower doses. Peaks of elevated body temperatures have been observed in 323 
some studies, although alterations in body weight are absent or minimal. Minor alterations in 324 
hematological parameters such as mild lymphopenia and neutrophilia have also been 325 
observed. SARS-CoV-2 virus shedding is observed in nasal and oropharyngeal swabs 46-49. 326 
As with Syrian hamsters, virus replication is detected in the upper respiratory tract very early 327 
after infection (day 2) and is detectable during two weeks of infection. Virus replication in 328 
ferrets appears to be restricted to the respiratory and GI tracts (Table 1).  329 
 330 
The predominant histopathology findings in SARS-CoV-2 infected ferrets euthanized at the 331 
peak of virus replication include mixed (pyogranulomatous or eosinophilic and histiocytic) 332 
inflammation within alveolar spaces and perivascular mononuclear inflammation.  In addition, 333 
in the larger airways of these animals, bronchial submucosal granulomatous foci with 334 
eosinophilic material and collagen fragments (suggesting collagen degeneration) were 335 
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observed.  Microscopic findings in euthanized animals were mild and included 336 
bronchoalveolar or alveolar inflammation.   337 
 338 
Ferrets also are able to transmit virus efficiently to uninfected animals in experimental 339 
settings. Efficient transmission occurred from experimentally infected ferrets to naïve cage 340 
mates; transmission from exposed ferrets to companion animals that were separated by steel 341 
grids did occur but was not efficient 48,50. These studies indicated that airborne transmission of 342 
SARS-CoV-2 can occur, and suggested that the ferret model may be useful for further 343 
transmission studies.  344 
 345 
Studies performed to date strongly indicate that experimental SARS-CoV-2 infection in ferrets 346 
results in a predominantly upper respiratory tract infection. These findings make the ferret 347 
model especially suited to test the efficacy of mucosal vaccines and therapeutics aimed to 348 
prevent upper airway infection and/or transmission.  349 
 350 
Non-Human Primate Models  351 
 352 
Non-human primate models have been explored for COVID-19 in rhesus macaques, 353 
cynomolgus macaques, and African green monkeys.  Studies from several laboratories have 354 
shown high levels of viral replication, including both viral RNA and infectious virus, in both the 355 
upper and lower respiratory tract, pathologic features of viral pneumonia, and variable 356 
induction of mild clinical disease 51-54.  Only mild clinical disease has been reported in 357 
nonhuman primates, and insufficient comparable data exists at this time to determine if there 358 
is more clinical disease in rhesus macaques, cynomolgus macaques, or African green 359 
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monkeys.  Induction of innate, humoral and cellular immune responses as well as robust 360 
protection against re-challenge has also been reported, demonstrating induction of natural 361 
protective immunity in this model 53. NHPs inoculated via multi-route mucosal, intrabronchial, 362 
or aerosol exposure routes showed radiographic abnormalities (chest X-ray, CT scan, or 363 
18FDG-PET scan) within two days that tended to resolve by days 11-15 post-infection. 364 
Evidence of live virus shedding has been found in both the respiratory and GI tract. In 365 
addition, hematological changes with evidence of T cell activation, mild lymphopenia and 366 
neutrophilia may be observed in infected NHPs.  367 
 368 
Infection with SARS-CoV-2 in the elderly is also associated with adverse clinical outcome.  369 
Currently, two NHP studies in rhesus and cynomolgus macaques have focused on the effect 370 
of age on SARS-CoV-2 infection 52,55. Both studies showed that aged animals shed virus from 371 
nose and throat for longer compared to young adult animals. In rhesus macaques, higher viral 372 
loads were also detected in lung tissue of aged animals. In addition, advanced age in rhesus 373 
macaques was also associated with increased radiological and histopathological changes. 374 
These studies highlight the importance of including age in the selection criteria of animals, as 375 
testing treatment options for severe disease require animal models that recapitulate the 376 
disease seen in humans. 377 
 378 
Recent studies have reported the immunogenicity and protective efficacy of prototype 379 
inactivated virus vaccines and DNA vaccines in the rhesus macaque model 56,57.  In these 380 
studies, the vaccines induced binding and neutralizing antibodies and resulted in substantial 381 
reductions of viral replication in the lower respiratory tract, and to a lesser extent the upper 382 
respiratory tract, following SARS-CoV-2 challenge.  These findings raise the possibility that 383 
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vaccines may be more effective at blocking lower respiratory tract disease compared with 384 
upper respiratory tract disease.  Anamnestic immune responses were observed following 385 
challenge, even in animals that had no virus detected after SARS-CoV-2 challenge, 386 
suggesting that protection with these particular vaccines is likely mediated by rapid 387 
immunologic control rather than true sterilizing protection.  Vaccine-elicited neutralizing 388 
antibody titers also correlated with protective efficacy 56. 389 
·     390 
Additional Animal Models  391 
 392 
Mink 393 
The mink (Neovison vison), which is listed in the zoological family Mustelidae, was shown 394 
previously to be susceptible to SARS-CoV infection 58and also mink lung epithelial cells and 395 
lung-derived cells could be infected with SARS-CoV 59. Minks also turned out to be naturally 396 
susceptible for SARS-CoV-2 infection. In the Netherlands, an infection of mink with SARS-397 
CoV-2 in two breeding farms was detected at the end of April 2020, most likely as the result of 398 
contact with a SARS-CoV-2-infected farm worker 60. In contrast to ferrets, minks displayed 399 
moderate respiratory signs which included labored breathing, and some animals died as a 400 
result of infection. SARS-CoV-2 virus was found in the majority of throat and rectal swabs, 401 
collected from dead animals from both farms. Similar to ferrets, the viral loads in mink were 402 
higher in the throat swabs than in the rectal swabs. While minks may represent a suitable 403 
model for moderate to severe COVID-19, these animals are difficult to handle under 404 






Three experiments so far have demonstrated that domestic cats (Felis catus) are highly 409 
susceptible to SARS-CoV-2 infection, and are able to transmit the virus to naïve contact cats 410 
49,61,62. For example, the inoculation of the Chinese SARS-CoV-2 isolate CTan-H through the 411 
intranasal route into juvenile (70-100 days old) and subadult cats (6-9 months old) resulted in 412 
virus replication in the upper and lower respiratory tract as well as the GI tract.  Both 413 
experimentally infected and contact cats seroconverted. At necropsy, interstitial pneumonia, 414 
loss of cilia and epithelial necrosis as well as inflammation in nasal turbinates and trachea 415 
were observed. The authors did not describe clinical signs in any of the infected cats, except 416 
that two juvenile cats (out of 10 total) died on day 3 and 13 post-infection 49. Virus antigen 417 
was found in epithelial cells of the nasal turbinates, necrotic debris in the tonsil, submucosal 418 
glands of the trachea and enterocytes of the small intestine. SARS-CoV-2 transmission by 419 
droplets was also demonstrated 49. While cats may represent a suitable model for 420 
asymptomatic to moderate COVID-19, the benefits should outweigh the concerns of using 421 
companion animals for research; also, cats are rather difficult to handle in biosafety level 3 422 
(BSL-3) containment and are not a standard animal model. However, due to their close 423 
contact to humans, additional studies e.g. on environmental contamination (cages, beds, 424 
food/water bowls, litterboxes, etc.) or transmission efficiency studies may be important to 425 
inform veterinary and public health authorities about the risk of cats as intermediate 426 





Dogs (Canis lupus familiaris) have been shown to be susceptible to SARS-CoV-2, but to a 430 
very mild degree. Two experiments so far have been published in this species, concluding 431 
that dogs have a low susceptibility to the SARS-CoV-2 infection 49,62.  432 
 433 
Pigs 434 
In silico data suggested that swine ACE2 should bind the SARS-CoV-2 spike protein. 435 
However, several experimental infections performed in pigs (Sus scrofa domesticus) by 436 
different research groups indicate that this species is not susceptible to SARS-CoV-2 infection 437 
in vivo 48,49.  No clinical signs and no clear evidence of virus replication have been observed 438 
in pigs.  Therefore, pigs do not appear to represent a suitable animal model for COVID-19. 439 
Conversely, previous studies reported SARS-CoV infection in pigs 63. Experimental infection 440 
of pigs with SARS-CoV resulted in detection of viral RNA in the blood and seroconversion, but 441 
not in clinical signs or virus isolation, which ruled out pigs as amplifying hosts for SARS-CoV 442 
64.  In contrast, infection with another bat betacoronavirus, called swine acute diarrhoea 443 
syndrome coronavirus (SADS-CoV), has been demonstrated in swine 65. Therefore, due to 444 
their importance as livestock species and the enormous global number of pigs, it may be still 445 
important for future studies to address the putative susceptibility of additional pig breeds to 446 
SARS-CoV-2 infection. 447 
 448 
Chickens and Ducks 449 
At least one in silico study using the informational spectrum methodology proposed chicken 450 
as a potential susceptible animal species for SARS-CoV-2 infection 66. However, the limited 451 
experimental studies performed so far have suggested that chicken, including embryonated 452 
chicken eggs, and ducks are not susceptible to SARS-CoV-2 infection 48,49. Neither chicken 453 
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nor ducks appear to represent suitable animal models for SARS-CoV-2 infection studies. 454 
These findings are similar to those previously reported for SARS-CoV infection, in which 455 
experimental inoculation of different bird species with SARS-CoV, including chickens, resulted 456 
in neither replication nor seroconversion 67.  457 
 458 
Fruit bats 459 
Bats are regarded as the natural reservoir of many coronaviruses including SARS-CoV and 460 
SARS-CoV-2 68,69. Intranasal inoculation of fruit bats (Rousettus aegyptiacus) with SARS-461 
CoV-2 resulted in efficient replication in the upper respiratory tract and seroconversion in 7 462 
out of 9 animals. Transmission occurred to one out of 3 direct contact animals. Clinical signs 463 
were absent, but rhinitis could be detected by immunohistology 48. Conversely, previous 464 
studies showed that a SARS-like coronavirus did not replicate in fruit bats after experimental 465 
inoculation 70. These findings suggest that, although Rousettus bats are not the original 466 
reservoir species of SARS-CoV-2, experimental infection of these fruit bats could help to 467 
model the physiopathology of the virus in its host.  468 
 469 
Preclinical Alternatives to Animal Models  470 
 471 
Historically animal alternatives for studying respiratory viruses have involved in vitro 472 
approaches such as cell lines (e.g. Vero cells, A549, MDCK) or primary tissue-derived human 473 
cells in conventional cell cull culture. However, over the past decade advances in 474 
engineering, cell biology, and microfabrication have come together to enable development of 475 
new human cell-based alternatives to animal models. In this regard, microengineered organs-476 
on-chips and lung organoids have been shown to support key hallmarks of the cytopathology 477 
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and inflammatory responses observed in human airways after infection with SARS-CoV-2 and 478 
have served to study human disease pathogenesis and test new candidate COVID-19 479 




Since SARS-CoV-2 emerged in the human population in late 2019, it has spread via human-484 
to-human transmission to most countries in the world, leading to a coronavirus pandemic of 485 
an unprecedented scale. Under the umbrella of the WHO, the WHO-COM is fostering the 486 
development of COVID-19 animal models through international exchange of protocols, 487 
unpublished data and ideas across many laboratories in the world. As discussed in this 488 
review, an important number of studies have been conducted, many of them by members of 489 
the WHO-COM, indicating that most of the animal models susceptible to infection with SARS-490 
CoV-2 show mild clinical disease, while others do not support viral replication.   491 
 492 
In studies based on the three dimensional X-ray structure of SARS-CoV-2 spike protein 493 
bound to human ACE2, Zhai et al discussed the variance observed between 19 different 494 
animal species as well as within three colonies of the same species of bat from different 495 
provinces within China. This analysis noted that many predicted ACE2 receptor affinities 496 
(especially dog and pig) did not match their relative natural resistance to SARS-CoV-2. This 497 
was proposed to be due to differences in the ACE2 expression levels between species in the 498 
respiratory epithelium 73. Similarly, a recent study aimed to predict the host range of SARS-499 
CoV-2 by a comparative structural analysis of ACE2 in more than 400 vertebrates. These 500 
data show discrepancies between the predicted susceptibilities and those experimentally 501 
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observed, with ferrets for example predicted to have very low susceptibility to infection 74. 502 
These data  suggest that susceptibility to infection may be a function of several factors, 503 
including genetic ACE2 composition, organ-specific ACE2 expression and other host factors 504 
such as additional receptors and host immune responses. 505 
 506 
One immediate goal of the group is to evaluate whether mimicking human co-morbidities, co-507 
infections or the immune senescence associated with age in these animal models may result 508 
in more severe disease phenotypes. The existing animal models have also been valuable for 509 
testing vaccines and therapeutics. Several vaccine candidates have shown protection in 510 
rhesus macaques 56,57, and both the cynomolgus and the rhesus macaque models have been 511 
useful for testing of therapeutics 75. Many of the pathogenesis studies described in this review 512 
have also highlighted an important caveat in COVID-19 research, which are the methods 513 
utilized to measure virus replication. The group found that viral RNA/genome copy numbers 514 
measured by qPCR assays were three to four orders of magnitude higher than infectious 515 
virus titers measured by cell culture assays. These findings have important implications for 516 
the future evaluation of vaccines and therapeutics.  517 
 518 
There have been concerns that coronaviruses might pose a risk of vaccine-associated 519 
enhanced respiratory disease (VAERD) or antibody-dependent enhancement (ADE) of virus 520 
entry and replication in Fc receptor-bearing cells 76. These types of syndromes have been 521 
linked to vaccines that induced substantial levels of non-neutralizing antibodies or type 2 522 
helper CD4 T cell (Th2) biased responses. Therefore, evaluating the relative potency of 523 
neutralizing activity to overall binding antibody and obtaining evidence for CD4 T cell subset 524 
biased responses through cytokine production or antibody subtype response patterns would 525 
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be informative. To ensure such models are able to provide these vital readouts, it is important 526 
to attempt to induce VAERD in COVID-19 challenge models using suboptimal doses of 527 
candidate vaccines or antigenic preparations specifically designed to induce the required 528 
detrimental immune profile and associated lung pathology. Such studies are of high priority 529 
for the WHO-COM group, which intends to provide some guidance on the potential for 530 
vaccine-elicited immunopathology.  In summary, the work presented here demonstrates that 531 
there are a number of potential small and large animal models that investigators can utilize to 532 
explore important aspects of COVID-19, including mechanisms underlying the pathology, 533 
transmission, and host response to the infection as well as the safety and efficacy of potential 534 
therapeutics or vaccines.  535 
 536 
Future studies should standardize challenge models to allow comparison of different vaccine 537 
candidates, and should establish animal models for assessing VAERD. In the context of 538 
VAERD, the establishment of a positive control allowing comparisons between different 539 
vaccine candidates in preclinical models is a high priority.  Continued refinement and 540 
development of COVID-19 animal models will contribute to the development of vaccines, 541 
therapeutics, and other countermeasures. 542 
 543 
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Table 1. SARS-CoV-2 infection in humans and in animal models. This table illustrates the 731 
main features of SARS-CoV-2 infection in animal models and whether these features are also 732 
present in human COVID-19. NHP: Non-human primates; CNS: Central nervous system; GI: 733 







Upper respiratory tract Humans, mice, hamsters, ferrets, NHP, minks, cats, bats 
Other organs Humans, hACE2 mice (CNS), hamsters, ferrets (GI tract), 
NHP (GI tract)
Pneumonia 
Bilateral lung involvement Humans, hamsters, NHP
Ground-glass opacities Humans, hamsters, NHP
ARDS Humans
Transmission 
Humans, hamsters, ferrets, cats, bats 
Demographics 
More severe disease: males Humans, hamsters
More severe disease: aged Humans, hamsters, NHP
Clinical signs 
Fever Humans, ferrets
Nasal discharge Humans, ferrets
Labored breathing Humans, hamsters 
Focal edema, inflammation Humans, hamsters, ferrets, NHP
Immunology 
Seroconversion Humans, hamsters, NHP, ferrets, bats, mice 
Neutralizing Ab titers Humans, hamsters, NHP, ferrets, mice
